אסטוניה - אסטונית - Ravimiamet

stada arzneimittel ag - fingolimood - kõvakapsel - 0,5mg 7tk

אסטוניה - אסטונית - Ravimiamet

stada arzneimittel ag - atsetüültsüsteiin - kihisev tablett - 200mg 10tk

אסטוניה - אסטונית - Ravimiamet

stada arzneimittel ag - atsetüültsüsteiin - kihisev tablett - 600mg 20tk; 600mg 10tk

אסטוניה - אסטונית - Ravimiamet

stada arzneimittel ag - ketokonasool - šampoon - 20mg 1g 60ml 1tk; 20mg 1g 100ml 1tk

אסטוניה - אסטונית - Ravimiamet

stada arzneimittel ag - lidokaiin+kummeliekstrakt - suuõõnegeel - 20mg+185mg 1g 10g 1tk

אסטוניה - אסטונית - Ravimiamet

stada arzneimittel ag - salitsüülhape+piimhape - nahalahus - 167mg+150mg 1ml 15ml 1tk

אסטוניה - אסטונית - Ravimiamet

stada arzneimittel ag - rutosiid - tablett - 500mg 30tk; 500mg 60tk; 500mg 100tk

אסטוניה - אסטונית - Ravimiamet

stada arzneimittel ag - dabigatraaneteksilaat - kõvakapsel - 110mg 60tk; 110mg 180tk; 110mg 30tk

אסטוניה - אסטונית - Ravimiamet

stada arzneimittel ag - tsilostasool - tablett - 50mg 14tk; 50mg 56tk

האיחוד האירופי - אסטונית - EMA (European Medicines Agency)

stada arzneimittel ag - bevatsizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastilised ained - oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. lisateavet inimese epidermaalse kasvufaktori retseptori 2 (her2) seisundi kohta vt palun 5. jaotisest. oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with oyavas in combination with capecitabine. her2 staatuse kohta lisateabe saamiseks lugege palun 5. jaotist. oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.